Research Nester released a report titled “CAR T-Cell Therapy Market: Global Demand Analysis & Opportunity Outlook 2028” which delivers detailed overview of the global CAR T-cell therapy market in terms of market segmentation by indication, by target antigen and by region.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, restraints, supply and demand risk, market attractiveness, BPS analysis and Porter’s five force model.
In recent years, the number of cases of cancer has risen significantly, leading to the need for effective and targeted therapies for its treatment. Chimeric Antigen Receptor T-cell therapy, commonly known as the CAR T-cell therapy, is a form of immunotherapy being developed for the treatment of cancer at a genetic as well as cellular level. The market for CAR T-cell therapy is projected to grow by a CAGR of around 35% over the forecast period, i.e., 2020-2028. The market is segmented by indication, by target antigen and by region. On the basis of indication, the market is further segmented into acute lymphoblastic leukemia (ALL), chronic lymphoblastic leukemia (CLL), multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL) and others. The segment for DLBCL is anticipated to hold the largest share in the market on account of growing cases of the condition which raise the demand for CAR T-cell therapy.
Based on region, the CAR T-cell therapy market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market is predicted to hold the leading share in the North America region. The growing research and developments taking place in the field of CAR T cell therapy and cancer treatments in the region along with increasing number of treatments receiving approval by the U.S. Food and Drug Administration (FDA) result in the market growth.
Increasing FDA Approvals for CAR T Cell Therapies to Expand the Market Size
In 2017, the U.S. FDA approved Kymriah, a CAR T cell therapy for the treatment of large B cell lymphoma in adult patients. The therapy, developed by Novartis, can further be used for the treatment of adult patients with acute lymphoblastic leukemia, diffuse large B cell lymphoma (DLBCL) and DLBCL arising due to follicular lymphoma.
The growing number of CAR T-cell therapies which have either been approved by the FDA or other regulatory authorities or are still undergoing the clinical trial phase are anticipated to result in the market growth. However, the various side effects associated with the CAR T cell therapy, such as cytokine release syndrome (CRS), headache, encephalopathy, nausea and bleeding among several others are estimated to restrict the market growth.
This report also provides the existing competitive scenario of some of the key players of the global CAR T-cell therapy market which includes company profiling of Novartis International AG, Gilead Sciences, Inc., Pfizer Inc., Johnson & Johnson, Amgen Inc., Bellicum Pharmaceuticals, Inc., Immune Therapeutics, Sorrento Therapeutics, Celgene Corporation and Bluebird Bio. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global CAR T-cell therapy market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.